Suppr超能文献

非配体依赖性血小板生成素突变体受体的内源性活性需要细胞表面定位。

Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.

作者信息

Marty Caroline, Chaligné Ronan, Lacout Catherine, Constantinescu Stefan N, Vainchenker William, Villeval Jean-Luc

机构信息

INSERM, U790, Villejuif 94805, France.

出版信息

J Biol Chem. 2009 May 1;284(18):11781-91. doi: 10.1074/jbc.M808703200. Epub 2009 Mar 4.

Abstract

The activating W515L mutation in the thrombopoietin receptor (MPL) has been identified in primary myelofibrosis and essential thrombocythemia. MPL belongs to a subset of the cytokine receptor superfamily that requires the JAK2 kinase for signaling. We examined whether the ligand-independent MPL(W515L) mutant could signal intracellularly. Addition of the endoplasmic reticulum (ER) retention KDEL sequence to the receptor C terminus efficiently locked MPL(W515L) within its natural ER/Golgi maturation pathway. In contrast to cells expressing the parental MPL(W515L), MPL(W515L)-KDEL-expressing FDC-P1 cells were unable to grow autonomously and to produce tumors in nude mice. When observed, tumor nodules resulted from in vivo selection of cells leaking the receptor at their surface. JAK2 co-immunoprecipitated with MPL(W515L)-KDEL but was not phosphorylated. We generated disulfide-bonded MPL(W515L) homodimers by the S402C substitution, both in the normal and KDEL context. Unlike MPL(W515L)-KDEL, MPL(W515L-S402C)-KDEL signaled constitutively and exhibited cell surface localization. These data establish that MPL(W515L) with appended JAK2 matures through the ER/Golgi system in an inactive conformation and suggest that the MPL(W515L)/JAK2 complex requires membrane localization for JAK2 phosphorylation, resulting in autonomous receptor signaling.

摘要

在原发性骨髓纤维化和原发性血小板增多症中已发现血小板生成素受体(MPL)存在激活型W515L突变。MPL属于细胞因子受体超家族的一个亚群,其信号传导需要JAK2激酶。我们研究了不依赖配体的MPL(W515L)突变体是否能在细胞内发出信号。在内质网(ER)保留KDEL序列添加到受体C末端后,可有效地将MPL(W515L)锁定在其天然的ER/高尔基体成熟途径中。与表达亲本MPL(W515L)的细胞不同,表达MPL(W515L)-KDEL的FDC-P1细胞无法自主生长,也无法在裸鼠体内产生肿瘤。当观察到时,肿瘤结节是由体内表面泄漏受体的细胞选择产生的。JAK2与MPL(W515L)-KDEL共免疫沉淀,但未被磷酸化。我们通过S402C取代在正常和KDEL背景下生成了二硫键连接的MPL(W515L)同源二聚体。与MPL(W515L)-KDEL不同,MPL(W515L-S402C)-KDEL组成性发出信号并表现出细胞表面定位。这些数据表明,附加JAK2的MPL(W515L)以无活性构象通过ER/高尔基体系统成熟,并表明MPL(W515L)/JAK2复合物需要膜定位才能使JAK2磷酸化,从而导致受体自主信号传导。

相似文献

1
Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.
J Biol Chem. 2009 May 1;284(18):11781-91. doi: 10.1074/jbc.M808703200. Epub 2009 Mar 4.
2
MPL W515L mutation in pediatric essential thrombocythemia.
Pediatr Blood Cancer. 2013 Aug;60(8):E52-4. doi: 10.1002/pbc.24500. Epub 2013 Feb 25.
3
JAK2 V617F and MPL W515L/K mutations in Korean patients with essential thrombocythemia.
Korean J Lab Med. 2010 Oct;30(5):474-6. doi: 10.3343/kjlm.2010.30.5.474.
4
JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.
5
MPL W515L mutation in Chinese patients with myeloproliferative diseases.
Leuk Lymphoma. 2008 May;49(5):955-8. doi: 10.1080/10428190802035966.
6
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Am J Hematol. 2012 Jul;87(7):746-7. doi: 10.1002/ajh.23229. Epub 2012 May 6.
7
JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.
Blood. 2014 Sep 25;124(13):2104-15. doi: 10.1182/blood-2014-03-559815. Epub 2014 Aug 20.

引用本文的文献

2
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.
Front Oncol. 2021 Mar 10;11:641613. doi: 10.3389/fonc.2021.641613. eCollection 2021.
3
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.
PLoS One. 2020 Jun 1;15(6):e0232801. doi: 10.1371/journal.pone.0232801. eCollection 2020.
4
His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor.
J Biol Chem. 2016 Feb 5;291(6):2974-87. doi: 10.1074/jbc.M115.696534. Epub 2015 Dec 1.
6
Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.
J Cell Biochem. 2014 Jan;115(1):8-16. doi: 10.1002/jcb.24647.
7
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis.
Nat Med. 2013 May;19(5):586-94. doi: 10.1038/nm.3150. Epub 2013 Apr 14.

本文引用的文献

1
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
Blood. 2008 Jul 1;112(1):141-9. doi: 10.1182/blood-2008-01-131664. Epub 2008 May 1.
2
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis.
Blood. 2007 Nov 15;110(10):3735-43. doi: 10.1182/blood-2007-05-089003. Epub 2007 Aug 20.
3
New thrombopoietic growth factors.
Blood. 2007 Jun 1;109(11):4607-16. doi: 10.1182/blood-2006-10-019315. Epub 2007 Feb 8.
4
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Blood. 2006 Nov 15;108(10):3472-6. doi: 10.1182/blood-2006-04-018879. Epub 2006 Jul 25.
5
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
PLoS Med. 2006 Jul;3(7):e270. doi: 10.1371/journal.pmed.0030270.
6
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
Blood. 2006 Sep 1;108(5):1652-60. doi: 10.1182/blood-2006-02-002030. Epub 2006 May 2.
7
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.
Blood. 2006 Mar 1;107(5):1864-71. doi: 10.1182/blood-2005-06-2600. Epub 2005 Oct 25.
8
Janus kinases affect thrombopoietin receptor cell surface localization and stability.
J Biol Chem. 2005 Jul 22;280(29):27251-61. doi: 10.1074/jbc.M501376200. Epub 2005 May 16.
9
The Janus kinases (Jaks).
Genome Biol. 2004;5(12):253. doi: 10.1186/gb-2004-5-12-253. Epub 2004 Nov 30.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验